88results about How to "Enhanced drug release" patented technology

Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering KATP channel openers with other drugs to treat diseases of humans and animals.

A chronotherapeutic pharmaceutical formulation comprising a core containing an active agent (e.g., a drug) and a surfactant and a delayed release compression coating comprising a natural or synthetic gum applied onto the surface of the core.

A drug-eluting medical device includes a catheter balloon completely or partially coated with paclitaxel in anhydrous crystalline form, having an immediate release and bioavailability of a therapeutically effective amount of paclitaxel at the intervention site. The balloon can be made of a polyether-polyamide block copolymer, or a polyester amide, or polyamide-12.

Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.

The invention is directed to a Pharmaceutical extended release system, particularly for oral administration, of a pH-dependent water-soluble active substance, comprising or essentially consisting of a) flibanserin or a pharmaceutically acceptable derivative thereof as active substance; b) one or more pharmaceutically acceptable pH-dependent polymers; c) one or more pharmaceutically acceptable pH-independent polymers; d) one or more pharmaceutically acceptable acids; and e) optionally one or more additives. The present invention provides a release profile of flibanserin which is independent on the pH in the gastrointestinal tract when administered orally resulting in a significantly improved bioavailability.

A medical device, polymer composition, and method for delivering substantially water-insoluble drugs to tissue at desired locations within the body. At least a portion of the exterior surface of the medical device is provided with a polymer coating. Incorporated in the polymer coating is a solution of at least one substantially water-insoluble drug in a volatile organic solvent. The medical device is positioned to a desired target location within the body, whereupon the drug diffuses out of the polymer coating.

Provided herein are drug delivery systems, such as self-nanoemulsifying drug delivery systems, self-emulsifying drug delivery systems and parenteral microemulsion formulations, suitable for parenteral or oral delivery to a subject. The drug delivery systems may comprise a benzimidazole derivative, e.g., mebendazole, an oil, a surfactant, a cosurfactant and a dipolar aprotic solvent in a microemulsion formulation. Also provided are methods for improving the bioavailability of a benzimidazole derivative during treatment of a pathophysiological condition by using a formulation combining a particular emulsion droplet diameter and ratio of the surfactant:cosurfactant therein, for increasing concentration and retention of a benzimidazole derivative in the lung via a parenterally administerable microemulsion with droplet size of about 35 nm to less than 100 nm and for defining hemolytically safe microemulsions of a benzimidazole derivative during a therapeutic treatment via a parenterally administerable microemulsion with a surfactant:cosurfactant content by weight of about 6% to 48%.

A transdermal patch containing a drug comprising formoterol and / or a salt, a solvent for the drug, a pressure-sensitive adhesive comprising an ethylene / vinyl acetate copolymer resin and at least one of a filler and a plasticizer. The patch is substantially water-free. The patch serves to promote percutaneous absorption of the formoterol and / or a salt thereof and allow the efficacy of the drug to stably persist for a long period of time. The patch is thus effective for diseases such as asthma, which can be cured or prevented by exciting beta-receptors.

The present invention relates to a liposome combination, which wrapped hydrophilic drugs in water layer and wrapped hydrophobic drugs in lipid bilayer; hydrophobic drugs are photosensitizers. Using light with appropriate wavelength to activate the photosensitizer in the hydrophobic layer can result in the production of singlet oxygen and the free radical, and cause the oxidizing and breaking of the carbon chain of the phospholipid, and influences the stability of the liposome and the releases of the drug. The singlet oxygen and the free radical will attack the cancer cells at the same time as a result of combining the photodynamic- and chemo-effects.

Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.

Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.

Disclosed is a polymer conjugate of folic acid or a folic acid derivative, wherein an amide bond is not used. The compound has chemical stability and adequate drug release rate in the living organism. Specifically disclosed is a polymer conjugate of folic acid or a folic acid derivative, wherein a substituent represented by formula (I) is bonded to a carboxy group of a block copolymer which is composed of a polyethylene glycol and a polymer having a carboxy group in a side chain, or a pharmacologically acceptable salt thereof.[In the formula, A represents a monocyclic or fused aromatic group; G represents an optionally substituted (C1-C6) alkylene group; Y represents a hydrogen atom or a substituent; and E represents a residue of folic acid or a folic acid derivative.]

Ultrasonic energy has been proven that at suitable frequency range (670-kHz to 2-MHz), ultrasound can be focused to a specific target, and the concentrated energy has sufficient high acoustic pressure so that capable of inducing localized blood-brain barrier (BBB) disruption, which has an important implication on noninvasively delivering drug into brain.

Pharmaceutical compositions of a benzimidazole or a benzimidazole derivative are disclosed. For example, in certain embodiments the pharmaceutical compositions include a benzimidazole, a polyol, and a dipolar aprotic solvent. In other embodiments, pharmaceutical compositions include a benzimidazole, an oil, a dipolar aproptic solvent, and a surfactant. In certain embodiments, the benzimidazole is mebendezole. The pharmaceutical compositions are formulated for delivery to a subject by any means, and include formulations for oral and parenteral delivery.

Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.

The invention is directed to a Pharmaceutical extended release system, particularly for oral administration, of a pH-dependent water-soluble active substance, comprising or essentially consisting ofa) flibanserin or a pharmaceutically acceptable derivative thereof as active substance;b) one or more pharmaceutically acceptable pH-dependent polymers;c) one or more pharmaceutically acceptable pH-independent polymers;d) one or more pharmaceutically acceptable acids; ande) optionally one or more additives.The present invention provides a release profile of flibanserin which is independent on the pH in the gastrointestinal tract when administered orally resulting in a significantly improved bioavailability.

A method for preparing a sericin hydrogel, the method including: 1) weighing a cocoon of a fibroin-deficient mutant silkworm, Bombyx mori, extracting the cocoon by an aqueous solution of LiBr or LiCl, dialyzing an extracted solution to yield a sericin solution having a concentration of a non-degraded sericin of between 0.1 and 4 wt. %; and 2) concentrating the sericin solution to a concentration of between 1.5 and 10 wt. %, adding a crosslinking agent to the concentrated sericin solution at a ratio of between 2 and 500 μL of the crosslinking agent per each milliliter of the sericin solution, fully blending the crosslinking agent with the concentrated sericin solution, and keeping a resulting mixture at the temperature of between 4 and 45° C. for between 5 s and 36 hrs to yield a hydrogel.

Disclosed herein are compounds comprising a polymer conjugated with a pH-sensitive prodrug of beta-lapachone, wherein the compound is capable of forming a micelle, and wherein the pH-sensitive prodrug comprises a pH-sensitive linker selected from the group consisting of: an aryl imine and an aliphatic imine. Also provided are micelles comprised of such polymer-prodrug conjugates. Further provided are methods for treating cancer with the micelles.

The present invention discloses an endogastric flotation slow-released administration system, including medicine-loaded shell body and medicine-loaded kernel body, in which said kernel body is placed in the interior of said shell body, in the interior of said kernel body the air is held, and the specific weight of said endogastric flotation show-released medicine is less than 1g / cm. Said invention also provides the method for preparing endogastric flotation slow-released administration system by utilizing three-dimensional printing forming technique.

A slow-releasing taxusol nanoparticle used for anticancer medicine is prepared through dissolving biodegradable high-molecular polyester, poloxamer 188 (or 407) or polyethylene glycol and taxusol in acetone, adding it to the aqueous solution of polyvinyl alcohol or poloxamer 188, removing acetone, centrifugal separation, washing with distilled water and freeze drying.

Implant systems and methods are provided to include a treatment material with a pelvic implant device. The pelvic implant device, such as an incontinence sling, can include the treatment coating combination of polycarbonate (PC) and an infection prevention material, such as InhibiZone® (IZ) technology. The treatment material can be coated onto, or impregnation or integrated with, polypropylene mesh in order to prevent infection and promote healing.

A novel hydrogel delivery systems useful for encapsulating and releasing pharmaceuticals or chemicals is disclosed where water soluble polymers containing crosslinker repeating units that associate or dissociate with complementary crosslinking repeating units or separate linkers to reversibly crosslink the hydrogel. In an exemplary embodiment, a DNA crosslinked hydrogel displays photoreversibility. An exemplary hydrogel delivery system comprises DNA polymer conjugates, wherein complementary DNA sequences are crosslinked with polymer chains and hybridization of the DNA sequences is controlled by photoresponsive moieties. Such hydrogels can be used to release drug molecules and / or other therapeutic reagents. The exemplary hydrogel employs photosensitive azobenzene moieties that are incorporated into the DNA crosslinker units. The azobenzene moieties respond to different wavelengths of light so that the state of azobenzene isomerization is induced by the proportion of visible and UV light irradiated. The isomer state of the azobenzene dictates whether the complementary DNA sequences hybridize to cross link the DNA polymer conjugates. Thus, irradiation of light (visible or UV) can transform the hydrogel network between a sol and any of multiple gel states to regulate the degree of crosslinking between complementary DNA sequences and, therefore, provide a profile of release of a hydrogel encapsulated pharmaceutical or other chemical.

Disclosed are systems and methods that can be utilized to define and control the delivery rate of a biological agent from a carrier matrix such as a biocompatible hydrogel. The carrier matrices of the present invention can include ligands incorporated within the matrix at a predetermined concentration level (CLT). In addition, the ligands within the matrix can display a particular, predetermined affinity for the biologically active agents to be delivered by the system. In particular, the affinity between the ligand and the biologically active agent can have a known predetermined dissociation constant (KD). When utilizing the system, the agent can be incorporated within the matrix due to association of the agent with the ligand. In addition, the agent can be protected from side reactions due to the association of the agent with the ligand. Through particular selection of the parameters CLT and KD, the rate of release of the biologically active agent from the matrix can be controlled. The disclosed methods and systems can be advantageously used in both in vivo clinical settings and ex vivo settings, such as tissue engineering applications.